ANGLE plc has announced the launch of its Portrait+ CTC staining kit at the San Antonio Breast Cancer Symposium. The kit is designed for the identification, characterisation, and enumeration of epithelial and mesenchymal cancer cells, including those undergoing epithelial-to-mesenchymal transition (EMT). EMT is a crucial step in cancer cell development and is associated with tumor progression, drug resistance, and metastasis. The kit combines ANGLE's Parsortix technology with an optimised immunofluorescent assay to provide accurate and repeatable results. It uses a direct staining technique and pre-mixed, freeze-dried antibodies for ease of use and long-term storage. The kit also includes ANGLE's CellKeep slide, which maximises the retention of CTCs harvested from blood samples for imaging. The Portrait+ CTC staining kit can be used in multiple cancer types, including breast, lung, prostate, and ovarian cancers. ANGLE's Founder and Chief Executive, Andrew Newland, stated that the kit has the potential to optimise study protocols and minimise costs for investigators. ANGLE will actively promote the test to academic and translational research customers.